Matthew Galsky, MD

Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai

Articles by Matthew Galsky, MD

Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
View More
Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | May 20, 2024
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Matthew Galsky, MDThe Uromigos | September 7, 2023
Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.
Matthew Galsky, MDASCO GU Symposium 2023 | February 24, 2023
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.